Pears, thanks for your look at this. Yes, there are a lot of open questions, but your overall view of the potential here syncs with mine. Usually, there is an interim report at 6 months and the full trial runs for a year. I'm unsure how Multistem is curative for stroke victims. One of the things that occurs to me, as a layman, is some type of cell "replacement" or "regeneration" with the infusion of fresh stem cells after a stroke. I understand the inflammation being lowered, but I think something more is happening, a type of healing that occurs similar to when stem cells are applied to a burn victim to regenerate skin and reduce scarring. The fact that MultiStem is tolerated as an infusion...and this is approved by the FDA for trials...seems very impressive. What else could this technique be used for? Very intriguing indeed. As for management, it seems focused and steady. When the pilot ischemic stroke trial results came in, the first criticisms were that the primary end points were not met at six months. But management was astute enough to realize that there was important evidence that for the 30+ hour group was improving. The trial was continued and at 1 year, this group has a major recovery. This is when I got interested in ATHX. The CEO is very focused and maybe a little difficult in making deals with potential partners. We may need a cash raise. But if the Japan trial goes well, then partners may be standing in line to infuse cash. Thanks again for looking at this. I have a core position, and I'm trading around it as the charts suggest. It's okay to buy some here and hold. ATHX is now getting some press, which will likely push the price up as trial progress is announced. - CARS
News 
Market Data 
Discover 
